Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Optimind Pharma (OMND) will begin trading on the CSE under the ticker symbol OMND
  • Optimind is a shareholder of Manitari Pharma
  • Manitari Pharma has submitted an application to Health Canada for a Controlled Substances Dealer’s Licence
  • Optimind specializes in prescribing medical cannabis and psychedelic-assisted therapies for various medical ailments

Optimind Pharma (OMND) will begin trading on the CSE under the ticker symbol OMND.

Medical cannabis has quickly become one of the most prescribed medications in Canada due to its efficacy and safety, which remains the primary business of the clinic.

Optimind is also an emerging provider of psychedelic therapies at its clinic, helping people suffering from PTSD, anxiety, depression, and other mental illnesses and disabilities by providing ketamine assisted treatment and other psychedelic enhanced psychotherapy modalities.

Optimind is a shareholder of Manitari Pharma. Manitari Pharma has submitted an application to Health Canada for a Controlled Substances Dealer’s Licence for Psilocybin Research Purposes.

Tomas Sipos, Chief Executive Officer at Optimind, commented on the news.

“The public listing of Optimind represents a significant milestone in the growth of our company. It’s an important step that will help facilitate our mission to provide psychedelic-assisted therapies for the public and improve their quality of life.”

Tony Clement, Chair of the Advisory Board at Optimind added,

“Optimind is on it’s way to becoming a leader in psychedelic-assisted therapy that will provide patients throughout North America with choices that promote mental, physical, and spiritual wellness. I’m supportive and enthusiastic to be a part of this exciting development and opportunity.”

“Psychedelic-assisted therapy has the power to drastically transform people’s lives around the world. At Optimind, our mission is to help people live life fully again through our treatment,” commented Dr. Michael Hart, Chief Operating Officer at Optimind.

Optimind specializes in prescribing medical cannabis and other alternative treatments for various medical ailments.


More From The Market Herald
Emerald Health Therapeutics Inc. - Director & Chairman, Jim Heppell.

" Emerald Health (CSE:EMH) shareholders approve merger

Emerald Health Therapeutics (EMH), has received shareholders’ approval for the proposed plan of arrangement with Skye Bioscience Inc.
Mydecine Innovations Group - CEO, Josh Bartch.

" Mydecine (NEO:MYCO) raises $244K and shifts management team

Mydecine Innovations Group (MYCO) has signed a common share subscription agreement with a third-party investor for proceeds up to $244,99.50.

" Lobe Sciences (CSE: LOBE) update psilocin compounds and development plans on site

Lobe Sciences (LOBE) is updating its corporate presentation describing plans for advancing the development of its psilocin analogues L-130 and L-131.
PharmaDrug - CEO, Daniel Cohen

" PharmaDrug (CSE:PHRX) completes milestone to support cGMP production of PD-001

PharmaDrug (PHRX) has laid the groundwork to support cGMP production of cepharanthine-2HCL for use in the drug product production of PD-001.